Corrected: BUZZ-VectivBio slips after stock offering

VectivBio Holding AG

14/10/2022 16:17

(Corrects link to press release in bullet 2; removes reference
to offer price being at a discount to VECT's closing price on
Oct. 13)
    ** Shares of drug developer VectivBio Holding AG  VECT.O 
fall 6.14% to $7.42
    ** Co on Oct 13 announces offer price of $7.50/share for its
offering of 16.7 mln ordinary shares, expects proceeds of nearly
$125 mln
    ** Co says investors who have agreed to purchase shares in
the offering include Cowen Healthcare Investments, Venrock
Healthcare Capital Partners and Vivo Capital, among others 
    ** VECT intends to use proceeds for clinical development of
its lead product candidate Apraglutide
    ** Co is developing Apraglutide as a potential treatment for
patients with short bowel syndrome that results from an
inability to absorb nutrients from food due to a short small
intestine 
    ** Including session's fall, stock up 50.4% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))